We showed that TGF-β1 treatment (5 ng/ml) for 30 or 60 min in Elovl5-silenced cancer cells induced a higher p-smad2/3 expression highlighting that the TGF-β pathway was more activatable (Fig. 4G and Supplementary Fig. S4E). The gene discussed is SMAD2; the disease is cancer.